和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00013 和黄医药

未开盘 08-07 16:08:13

19.480

+1.020

+5.53%

最高19.780	最低18.480	成交量1,086万
今开18.590	昨收18.460	日振幅7.04%
总市值169.87亿	流通市值169.87亿	总股本8.72亿
成交额2.11亿	换手率1.25%	流通股本8.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":19.48,"timestamp":1786090093003,"preClose":18.46,"halted":0,"volume":10860150,"delay":0,"changeRate":0.05525460455037917,"floatShares":872000000,"shares":872000000,"eps":4.079415387270631,"marketStatus":"未开盘","change":1.02,"latestTime":"08-07 16:08:13","open":18.59,"high":19.78,"low":18.48,"amount":210768168,"amplitude":0.070423,"askPrice":19.49,"askSize":236000,"bidPrice":19.48,"bidSize":76500,"shortable":3,"etf":0,"ttmEps":0.15839145203931937,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786325400000},"marketStatusCode":0,"adr":0,"listingDate":1624982400000,"exchange":"SEHK","adjPreClose":18.46,"openAndCloseTimeList":[[1786066200000,1786075200000],[1786078800000,1786089600000]],"volumeRatio":3.339185333705322,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013","defaultTab":"news","newsList":[{"id":"2657155005","title":"【券商聚焦】申万宏源维持和黄医药（00013）买入评级 指呋喹替尼海外持续放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2657155005","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657155005?lang=zh_cn&edition=full","pubTime":"2026-08-05 14:38","pubTimestamp":1785911894,"startTime":"0","endTime":"0","summary":"金吾财讯 | 申万宏源发布研报指，和黄医药 2026年上半年收入2.78亿美元，同比增长0.2%，净利润为1,600万美元，同比下降96.5%，主因去年同期确认上海和黄药业处置收益，业绩符合预期。呋喹替尼海外市场持续拓展是核心亮点。研报预计，随着市场份额及医保覆盖范围扩大，其海外销售额有望进一步增长。考虑到呋喹替尼海外市场持续放量，申万宏源将26年的每股盈利预测从0.04美元上调至0.06美元，将27年预测从0.08美元上调至0.09美元，新增28年预测为0.10美元。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987535","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000166","HCM","KCE","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176871663","title":"和黄医药更新2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1176871663","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176871663?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:40","pubTimestamp":1785746415,"startTime":"0","endTime":"0","summary":"和黄医药（中国）有限公司于2026年8月3日发布了截至2026年7月31日的证券变动月报。报告显示，公司在本报告期内已发行及注册股本维持稳定，公示的股本数量和所持库藏股份均未出现变动。截至2026年7月31日，公司已发行普通股数量为872,335,120股，库藏股份数量为0股，较上月末均无变化。公司进一步确认，当前公众持股量满足香港联合交易所有限公司主板上市规则的相关要求。本次公告由公司非执行董事兼公司秘书施熙德签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656342224","title":"瑞银：降和黄医药(00013)目标价至29.5港元 续予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2656342224","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656342224?lang=zh_cn&edition=full","pubTime":"2026-08-03 11:24","pubTimestamp":1785727484,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，和黄医药(00013)上半收入同比增0.2%，大致符合该行预期。肿瘤或免疫业务收入同比增长13%，高于该行预期；纯利1,590万美元，去年同期为4.55亿美元，主要是由于去年同期确认了出售上海医药合营的一次性收益。该行将阿斯利康的里程碑延后至2027年，并修正开支预测，导致2026年的每股盈测下调，而2027年的预测则已由6美仙上调至8美仙。该行将公司目标价由29.7港元下调至29.5港元，续予“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00013","HCM","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656818342","title":"大行评级丨瑞银：微降和黄医药目标价至29.5港元，续予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2656818342","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656818342?lang=zh_cn&edition=full","pubTime":"2026-08-03 10:57","pubTimestamp":1785725823,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","BK4531","EWH","BK4007","BK1191","BK4588","HCM","00013","BK1587","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655362398","title":"和黄医药发布中期业绩 2026年上半年净利骤降96.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655362398","media":"经济参考网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655362398?lang=zh_cn&edition=full","pubTime":"2026-07-31 22:06","pubTimestamp":1785506816,"startTime":"0","endTime":"0","summary":"和黄医药（中国）有限公司（简称“和黄医药”，00013.HK）7月30日晚间发布2026年中期业绩公告，上半年公司实现收入总额2.78亿美元，同比增长0.22%；归属于母公司所有者的净利润为1592.80万美元，同比下降96.50%，主要由于2025年同期包含出售上海和黄药业45%股权所得一次性收益4.16亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313828677510.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313828677510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK4531","BK1191","00013","HCM","BK1588","BK1587","BK4007","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655938258","title":"粤十数智、星宇股份、汉得信息递表港交所；和黄医药、先声药业、美图公司发布2026年中期业绩预告丨港交所早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2655938258","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655938258?lang=zh_cn&edition=full","pubTime":"2026-07-31 07:01","pubTimestamp":1785452474,"startTime":"0","endTime":"0","summary":"｜2026年7月31日星期五｜NO.1粤十数智、星宇股份、汉得信息递表港交所据港交所7月29日披露，深圳粤十数智股份有限公司（以下简称粤十数智）、常州星宇车灯股份有限公司（以下简称星宇股份，SH601799）、上海汉得信息技术股份有限公司（以下简称汉得信息，SZ300170）已向港交所主板递交上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313827197718.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313827197718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","IE00B5MMRT66.SGD","02096","BK0188","300170","BK1609","LU2045819591.USD","BK1583","LU0082770016.USD","IE00BPRC5H50.USD","LU0082770016.SGD","IE00B543WZ88.USD","BK1612","00013","BK0070","01357","IPOS","601799","LU0164939612.USD","BK1587","HCM","BK1588","LU2125910500.SGD","BK4531","BK4585","BK1618","LU2125910849.SGD","BK1095","BK1191","SG9999006597.SGD","SG9999001093.SGD","BK1613","BK0065","BK0231","BK0264","BK4007","LU0620787316.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655874290","title":"和黄医药：2026年上半年净收益为1624万美元 同比降96.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655874290","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655874290?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:42","pubTimestamp":1785411720,"startTime":"0","endTime":"0","summary":"7月30日，和黄医药（00013/HCM）发布2026年中期业绩，公司收入总额2.78亿美元，同比增长0.22%；净收益为1624万美元，同比减少96.43%；每股普通股基本盈利0.02美元。在管理层讨论与分析中提到，爱优特?和苏泰达?的强劲市场销售反映了公司商业团队针对中国市场监管指引变化所采取的有效措施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607303826904289.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607303826904289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4531","BK4585","BK4007","HCM","00013","BK4588","BK1191","BK1587","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655879988","title":"和黄医药(00013.HK)发布中期业绩 股东应占净收益1624.2万美元 同比减少96.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655879988","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655879988?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:09","pubTimestamp":1785409741,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1588","BK1587","00013","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177832285","title":"和黄医药（00013）发布2026年中期业绩：总收入2.78亿美元 净利润1590万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177832285","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177832285?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:05","pubTimestamp":1785409551,"startTime":"0","endTime":"0","summary":"2026年7月30日，和黄医药披露截至2026年6月30日止六个月中期业绩。公司期内综合收入为2.783亿美元，与上年同期基本持平。沃瑞沙市场销售额1,570万美元，同比增长3%；综合收入1,330万美元，同比增长48%。截至2026年6月30日，公司现金及现金等价物和短期投资合计13.748亿美元，较2025年末的13.673亿美元有所增加。公司重申2026年肿瘤/免疫业务全年收入指引保持在3.3亿至4.5亿美元区间。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654458022","title":"【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2654458022","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654458022?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:01","pubTimestamp":1785204072,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，近一个月恒生医疗保健指数涨17.4%，跑赢大市。其中，生物药、CXO及处方药板块表现较优于其他板块。机构持仓方面，2026年年中以来，内资持仓延续提升态势，而外资则略有降低。该机构指，中报季临近，7月以来多家公司业绩预告陆续发布，CXO板块表现亮眼，业绩和订单延续高增长态势。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986903","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","06160","LU1720050803.USD","LU2097828714.EUR","LU2476274308.USD","LU0856984785.SGD","HK0000320223.HKD","06078","01177","01548","01952","LU0417516571.SGD","06990","01951","09996","BK1521","01276","01801","BK1219","LU0572944931.SGD","KURE","02162","06821","02268","LU1813983027.USD","01530","09966","06996","LU2399975544.HKD","02269","02596","01093","02273","09926","159938","09939","LU1880383366.USD","KCE","LU0588546209.SGD","LU0348783233.USD","03329","02096","03759","LU2039709279.SGD","LU0634319403.HKD","LU2328871848.SGD","HK0000165453.HKD","00013","BK1587","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177286233","title":"财报前瞻｜和黄医药营收结构以创新药与其他业务为主，本季度机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1177286233","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177286233?lang=zh_cn&edition=full","pubTime":"2026-07-23 12:34","pubTimestamp":1784781263,"startTime":"0","endTime":"0","summary":"和黄医药将于2026年07月30日发布最新季度财报，市场关注创新药商业化推进与费用控制节奏对盈利的影响。由于缺乏一致预期及公司在上季度披露中针对本季度的明确预测数据，当前市场对和黄医药本季度的营收、毛利率、净利润或净利率、调整后每股收益尚无可用的量化预测信息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜和黄医药营收结构以创新药与其他业务为主，本季度机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161904422","title":"和黄医药更新2026年6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1161904422","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161904422?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:55","pubTimestamp":1782982504,"startTime":"0","endTime":"0","summary":"和黄医药（中国）有限公司于2026年7月2日披露截至2026年6月30日的股份变动月报表。在本月内，公司已发行股份总数为872,335,120股，库藏股份数量为0股，均与上月底保持一致，整体股本结构稳定。公司同时确认，截至2026年6月30日，已符合适用的公众持股量要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647636536","title":"和黄医药：上半财年业绩公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2647636536","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647636536?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:33","pubTimestamp":1782808380,"startTime":"0","endTime":"0","summary":"南财智讯6月30日电，和黄医药（00013.HK）公告，公司将于2026年7月30日召开董事会会议，批准截至2026年6月30日止六个月之中期业绩，并于同日发布。业绩发布后，管理层将于当日20:00（香港时间）举行英文网上直播简报会，并于2026年7月31日08:30（香港时间）举行中文（普通话）网上直播。相关简报文稿将提前上传至公司官网，视频回放亦将在简报会结束后上线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606303788357319.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606303788357319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK1588","BK1587","BK4588","BK1191","HCM","BK4007","BK4531","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646782633","title":"港股异动 | 和黄医药(00013.HK)午前涨超3% 凡瑞格拉替尼关键性研究数据将于ESMO胃肠道肿瘤大会上公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2646782633","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646782633?lang=zh_cn&edition=full","pubTime":"2026-06-25 11:45","pubTimestamp":1782359107,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00013","BK1191","BK1587","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643822932","title":"【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2643822932","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643822932?lang=zh_cn&edition=full","pubTime":"2026-06-15 10:21","pubTimestamp":1781490116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，医药行业在1H26表现整体稳健、但内部分化也较为明显。短期关注出海交易、业绩表现和利好政策落地。推荐高景气度赛道中、投资性价比较高的头部玩家，包括药明合联、凯莱英和康龙化成。2026年港股龙头收入和净利润增速有望稳定在双位数。板块复苏积极信号已经出现。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320264.USD","02268","LU0737861772.HKD","06821","BK1576","06996","LU0456827905.SGD","01177","01951","LU1226287875.USD","09996","LU2399975544.HKD","03759","02096","03329","BK1191","LU0320764599.SGD","00013","02162","LU0181495838.USD","01276","03692","IE00B0JY6N72.USD","LU0140636845.USD","06990","LU1242518857.USD","02269","09966","LU3063872942.SGD","LU0819121731.USD","LU1688375341.USD","01548","06160","LU2097828631.EUR","LU1960683339.HKD","SG9999002562.SGD","LU0051755006.USD","02596","06078","09926","01952","IE00BZ08YR35.GBP","02273","01093","01530","LU0502904849.HKD","HK0000306685.HKD","LU1880383366.USD","01801","LU0348827113.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121028232","title":"和黄医药更新5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1121028232","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121028232?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:42","pubTimestamp":1780306938,"startTime":"0","endTime":"0","summary":"和黄医药（中国）有限公司于2026年6月1日发布2026年5月股份变动月报，报告期为2026年5月。在期权与激励计划方面，公司于2015年4月24日有条件采纳的认股权计划已于2026年5月12日到期，期末尚有23,346,922份股份期权未行使，当月另有642,700份期权失效。另于2026年5月12日新采纳的认股权计划最高可发行43,616,756股，目前尚未有期权授出或行使。公司确认，截至5月末，公众持股量符合香港联交所最低要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638166837","title":"港股异动 | 创新药概念股集体走低 加息预期压制行业估值及投融资环境 市场关注ASCO会议进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2638166837","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638166837?lang=zh_cn&edition=full","pubTime":"2026-05-28 15:09","pubTimestamp":1779952150,"startTime":"0","endTime":"0","summary":"创新药、CXO 等成长赛道对流动性较为敏感，若美联储降息周期延后，或国内降准降息落地不及预期，市场流动性收紧将直接压制成长赛道估值。值得注意的是，2026年美国临床肿瘤学会年会将于5月29日至6月2日在美国芝加哥举行。本届ASCO共63项研究入选LBA，其中12家企业的13项研究来自中国，创历史新高；同时，94项中国研究入选口头汇报，数量近三年快速增长。上海证券指出，中国药企在国际平台彰显实力，中国创新药全球话语权逐年提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1161","VXUS","BK4585","LU2097828631.EUR","LU2328871848.SGD","LU2242644610.SGD","159992","IE00BZ08YT58.USD","BK1588","LU0455707207.USD","LU2097828557.USD","01801","BK1521","LU1969619763.USD","LU2097828805.USD","01177","00013","BK1574","03692","BK1587","BK4588","HK0000165453.HKD","LU0502904849.HKD","BK1583","BK1589","LU2097828474.EUR","06978","LU2488822045.USD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","BK1515","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637361344","title":"和黄医药(00013)：股价刷新年内新低，何时迎变盘节点？","url":"https://stock-news.laohu8.com/highlight/detail?id=2637361344","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637361344?lang=zh_cn&edition=full","pubTime":"2026-05-22 09:50","pubTimestamp":1779414620,"startTime":"0","endTime":"0","summary":"4月21日，CDE官网公示，和黄医药自主研发的醋酸索乐匹尼布片提交了用于治疗温抗体型自身免疫性溶血性贫血患者的新适应症上市申请。截至5月21日，和黄医药股价已跌破19港元。已进入明显低估区间5月20日盘中，和黄医药股价最低触及18.57港元，对应市值为161.93亿港元，刷新年内新低。在基本面支撑叠加严重低估情况下，和黄医药的短线上的变盘节点值得投资者期待。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4007","00013","BK1588","HCM","BK4585","BK1587","BK4531","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637365831","title":"和黄医药(00013)将于美国临床肿瘤学会(ASCO)2026年年会上公布数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2637365831","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637365831?lang=zh_cn&edition=full","pubTime":"2026-05-22 08:20","pubTimestamp":1779409235,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，和黄医药自主研发的化合物的数项研究的最新及更新后的数据将于2026年5月29日至6月2日在美国芝加哥召开的美国临床肿瘤学会年会上公布。该研究已达到主要终点，即根据RECIST 1.1标准经独立审查委员会评估的客观缓解率 。至数据截止日2025年10月8日，IRC评估的ORR为32.3% ，超过了预设的疗效阈值。这些数据支持了向中国国家药品监督管理局提交新药上市申请，该申请已于2025年12月获受理并纳入优先审评。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK4585","HCM","BK1191","BK1588","00013","BK4007","BK4531","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198470954","title":"和黄医药与信达生物联合宣布：爱优特®（呋喹替尼）联合达伯舒®（信迪利单抗注射液）获NMPA批准用于治疗局部晚期或转移性肾细胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1198470954","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198470954?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:02","pubTimestamp":1779357741,"startTime":"0","endTime":"0","summary":"和黄医药与信达生物今日共同发布公告，宣布其合作开发的联合疗法——爱优特®（呋喹替尼）与达伯舒®（信迪利单抗注射液）——已正式获得中国国家药品监督管理局的上市批准。该联合疗法获批用于治疗局部晚期或转移性肾细胞癌患者，为这一领域的临床治疗提供了新的重要选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0502904849.HKD","LU2097828474.EUR","LU1969619763.USD","LU2097828714.EUR","LU2242644610.SGD","LU0455707207.USD","BK1191","BK1588","BK1161","BK1587","LU2097828805.USD","BK1583","LU2488822045.USD","01801","LU2328871848.SGD","00013","LU2097828631.EUR","LU2097828557.USD","HK0000165453.HKD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":0.0999},{"period":"1month","weight":0.0932},{"period":"3month","weight":-0.0724},{"period":"6month","weight":-0.1668},{"period":"1year","weight":-0.3048},{"period":"ytd","weight":-0.0553}],"compareEarnings":[{"period":"1week","weight":-0.0084},{"period":"1month","weight":0.0607},{"period":"3month","weight":-0.0275},{"period":"6month","weight":-0.0336},{"period":"1year","weight":0.0234},{"period":"ytd","weight":0.0015}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.066388},{"month":2,"riseRate":0.6,"avgChangeRate":0.075835},{"month":3,"riseRate":0.2,"avgChangeRate":-0.093928},{"month":4,"riseRate":0.4,"avgChangeRate":0.010831},{"month":5,"riseRate":0,"avgChangeRate":-0.149846},{"month":6,"riseRate":0.4,"avgChangeRate":0.004362},{"month":7,"riseRate":1,"avgChangeRate":0.132805},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.046926},{"month":9,"riseRate":0.6,"avgChangeRate":-0.004654},{"month":10,"riseRate":0.2,"avgChangeRate":-0.040611},{"month":11,"riseRate":0.4,"avgChangeRate":0.13917},{"month":12,"riseRate":0.4,"avgChangeRate":-0.030017}],"exchange":"SEHK","name":"和黄医药","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}